propofol unveiled: a novel approach to inducing diabetes in wistar rats

Alloxan and streptozotocin are commonly used to induce diabetes in animal models. theydestroy pancreatic beta cells through different mechanisms. however, their limitationsinclude laboratory toxicity and low efficacy at high doses. combining a new generation ofdiabetes-inducing agents with propofol offers improved efficiency, effectiveness, and costeffectiveness. both substances cause diabetes by generating reactive oxygen species, but thesource of these radicals differs. alloxan and its reduced product, dialuric acid, createsuperoxide radicals, leading to pancreatic tissue damage. streptozotocin enters beta cellsthrough glut2 and induces dna alkylation, depleting nad+and atp levels, andincreasing xanthine oxidase enzyme activity. propofol intensifies the defects caused by theother substances, triggering nerve pathways that inhibit repair and producing free radicals,which damage the pancreas. in the study, alloxan, streptozotocin, and propofol induceddiabetes in 40 wistar laboratory rats, resulting in hyperglycemia and reduced insulinsecretion.